uploads/2018/05/Chart-003-1.jpg

AstraZeneca’s 1Q18 Estimates: Respiratory Products

By

Updated

Respiratory products

AstraZeneca’s (AZN) growth platforms include its Respiratory segment. Its respiratory products include drugs such as Symbicort, Pulmicort, Bevespi, Duaklir, Daliresp, and Tudorza/Eklira.

The Respiratory segment is expected to report growth in revenue during 1Q18 compared to 1Q17. This revenue growth is expected to be driven by the strong sales of drugs such as Pulmicort, Duaklir, Daliresp, and Tudorza/Eklira, partially offset by lower sales of Symbicort and a few other products during the quarter.

The chart above compares the revenues for AZN’s key respiratory products since 1Q17.

Article continues below advertisement

Symbicort

Symbicort (budesonide/formoterol fumarate dihydrate) is one of the best-selling drugs from AstraZeneca’s portfolio. Symbicort is approved for use in patients with asthma and chronic obstructive pulmonary disease (or COPD). Symbicort’s revenue is expected to decrease during 1Q18 following lower sales in European markets and established markets in the rest of the world, partially offset by strong sales in US and emerging markets.

Pulmicort

Pulmicort (budesonide inhalation powder) is an inhaled corticosteroid and is approved as a maintenance treatment for asthma. Pulmicort is expected to report growth in revenue during 1Q18 following strong sales in US and emerging markets, partially offset by lower sales in European markets and established markets in the rest of the world.

Other drugs

Other respiratory drugs from AstraZeneca’s portfolio include Bevespi, Daliresp, Duaklir, and Tudorza/Eklira.

Daliresp is expected to report growth in revenue in 1Q18 following strong sales in US and European markets.

Duaklir is expected to report growth in revenue in 1Q18 following strong sales in European markets.

Tudorza/Eklira is expected to report growth in revenue in 1Q18 following strong sales in US markets, European markets, and established markets in the rest of the world.

The VanEck Vectors Pharmaceuticals ETF (PPH) holds 5.4% of its total investments in AstraZeneca’s ADR (American depositary receipt), 5.5% in Merck & Company (MRK), 4.9% in Johnson & Johnson (JNJ), and 4.8% in Eli Lilly and Company (LLY).

Advertisement

More From Market Realist